Morbidity and mortality in pregnancy: laying the groundwork for safe motherhood

Stacie E Geller1, Suzanne M Cox, William M Callaghan

  • 1Department of Obstetrics and Gynecology, College of Medicine, University of Illinois at Chicago, 60612, USA. sgeller@uic.edu

The Safe Motherhood Initiative is a global effort to reduce deaths and illnesses among women and infants. Despite the relatively low maternal mortality rate in the United States, ensuring safe motherhood is still critical. For several reasons, it is important to study maternal mortality and morbidity. First, the pregnancy-related mortality ratio has not declined; second, evidence suggests that at least half of pregnancy-related deaths may be preventable through changes in patient, provider, or system factors; and third, mortality rates are disproportionately high among certain racial and ethnic groups. In addition, deaths are only the tip of the iceberg: maternal morbidity also represents a huge burden of disease for women and their families. Broadening the research focus and prevention efforts to include the study of maternal morbidity, especially near-miss morbidity-life-threatening morbidity-can strengthen the study of maternal death. This paper presents an overview of maternal mortality and morbidity including incidence and etiology, issues and challenges for measurement, and issues of preventability. We also address specific strategies for change for health care providers, federal and state health agencies, and the public health community.

Related Concept Videos

Development of the Oral Microbiota01:28

Development of the Oral Microbiota

The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Malaria01:29

Malaria

Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
Development of Human Microbiota01:30

Development of Human Microbiota

The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from the skin...